Bookmark
Forward
QuickView for Vindesine (compound)
PubChem
| Name: | Vindesine |
|---|---|
| PubChem Compound ID: | 11643449 |
| Description: | Vinblastine derivative with antineoplastic activity against CANCER. Major side effects are myelosuppression and neurotoxicity. Vindesine is used extensively in chemotherapy protocols (ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS). |
| Molecular formula: | C43H55N5O7 |
| Molecular weight: | 753.926 g/mol |
DrugBank
Identification
| Name: | Vindesine |
|---|---|
| Name (isomeric): | DB00309 |
| Drug Type: | small molecule |
| Description: | Vinblastine derivative with antineoplastic activity against CANCER. Major side effects are myelosuppression and neurotoxicity. Vindesine is used extensively in chemotherapy protocols (ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS). |
| Synonyms: |
Vindesine Sulfate; Desacetylvinblastine Amide Sulfate
|
| Brand: | Eldesine, Eldisine, DAVA |
| Category: | Antineoplastic Agents, Tubulin Modulators, Antineoplastic Agents, Phytogenic |
| CAS number: | 59917-39-4 |
Pharmacology
| Indication: | For the treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia and acute panmyelosis |
|---|---|
| Pharmacology: |
Vindesine is indicated for the treatment of acute lymphocytic leukemia of childhood that is resistant to vincristine and non-oat cell lung cancer.Vindesine causes the arrest of cells in metaphase mitosis. It is three times more potent than vincristine and nearly 10 times more potent than vinblastine in causing mitotic arrest in in vitro stud...
show more » |
| Mechanism of Action: | Vindesine acts by causing the arrest of cells in metaphase mitosis through its inhibition tubulin mitotic funcitoning. The drug is cell-cycle specific for the S phase. |
| Protein binding: | 65-75% |
| Biotransformation: | Hepatic |
| Half Life: | 24 hours. |
| Affected organisms: | Humans and other mammals |
Interactions
| Drug interaction: |
|
|---|
Targets
Enzymes
